文献速递临床试验与 GCP流行病学与生物统计

多营养素补充与食物相关行为激活治疗对超重或肥胖伴亚综合征抑郁症状成人预防重性抑郁障碍的效果:MooDFOOD随机临床试验

Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

该多中心2×2析因随机临床试验纳入1025例体重指数25-40、患者健康问卷-9评分≥5且近6个月无重性抑郁障碍发作的超重成人,比较每日多营养素补充与安慰剂、21次个体或团体治疗与无治疗及其组合对1年重性抑郁障碍累积发病的影响。结果显示各干预均未影响重性抑郁障碍发生,补充剂比值比为1.06(95%CI 0.87-1.29),治疗为0.93(95%CI 0.76-1.13),联合为0.93(95%CI 0.76-1.14;交互作用P=0.48)。

要点

  • 在超重或肥胖伴亚综合征抑郁症状成人中,多营养素补充与安慰剂相比未减少1年内重性抑郁障碍发作。
  • 食物相关行为激活治疗与无治疗相比未减少1年内重性抑郁障碍发作,联合干预亦无效果。
  • 这些发现不支持使用上述干预措施预防重性抑郁障碍。

核心结论

  • 在超重或肥胖伴亚综合征抑郁症状成人中,与安慰剂相比多营养素补充、与无治疗相比食物相关行为激活治疗均未减少1年内重性抑郁障碍发作。
  • 这些发现不支持使用这些干预措施预防重性抑郁障碍。

研究设计与样本

  • 多中心2×2析因随机临床试验,纳入体重指数25-40、患者健康问卷-9评分≥5且近6个月无重性抑郁障碍发作的超重成人,来自4个欧洲国家。
  • 共1025例成人被随机分组(2015年7月30日至2016年10月12日),随访1年(至2017年10月13日)。
  • 干预为每日多营养素补充剂(1412毫克ω-3脂肪酸、30微克硒、400微克叶酸、20微克维生素D3加100毫克钙)与安慰剂比较,以及21次个体或团体治疗与无治疗比较(研究者盲法),持续1年。
  • 分组为安慰剂无治疗组(n=257)、安慰剂加治疗组(n=256)、补充剂无治疗组(n=256)、补充剂加治疗组(n=256)。

主要发现

  • 1025例参与者平均年龄46.5岁,女性772例(75%),平均体重指数31.4,779例(76%)完成试验。
  • 12个月随访期间105例(10%)发生重性抑郁障碍:安慰剂无治疗组25例(9.7%)、安慰剂加治疗组26例(10.2%)、补充剂无治疗组32例(12.5%)、补充剂加治疗组22例(8.6%)。
  • 补充剂比值比为1.06(95%CI 0.87-1.29),治疗为0.93(95%CI 0.76-1.13),联合为0.93(95%CI 0.76-1.14;交互作用P=0.48)。
  • 补充剂加治疗组1例死亡;安慰剂两组各24例住院,补充剂加治疗组24例住院,仅补充剂组26例住院。

临床怎么用

  • 原文结论为这些发现不支持使用多营养素补充或食物相关行为激活治疗预防重性抑郁障碍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown. OBJECTIVE: To examine the effect of 2 nutritional strategies (multinutrient supplementation, food-related behavioral activation therapy) and their combination for prevention of a new MDD episode in overweight adults with subsyndromal depressive symptoms. DESIGN, SETTING, AND PARTICIPANTS: This multicenter 2 × 2 factorial randomized clinical trial included overweight adults (body mass index, 25-40) with elevated depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] scores ≥5) and no MDD episode in the past 6 months from 4 European countries. A total of 1025 adults were randomized (July 30, 2015-October 12, 2016) and followed up for 1 year (October 13, 2017). INTERVENTIONS: Daily multinutrient supplements (1412-mg omega-3 fatty acids, 30-μg selenium, 400-μg folic acid, and 20-μg vitamin D3 plus 100-mg calcium) vs placebo and 21 individual or group therapy sessions vs none (blinded to researchers) for 1 year. Participants were allocated to placebo without therapy (n = 257), placebo with therapy (n = 256), supplements without therapy (n = 256), and supplements with therapy (n = 256). MAIN OUTCOME AND MEASURES: Cumulative 1-year onset of MDD via the Mini International Neuropsychiatric Interview at 3, 6, and 12 months. Logistic regression using effect-coded variables (-1 indicating control, 1 indicating intervention) evaluated intervention effects both individually and in combination (interaction) on MDD onset. RESULTS: Among 1025 participants (mean age, 46.5 years; 772 women [75%]; mean BMI, 31.4), 779 (76%) completed the trial. During the 12-month follow-up, 105 (10%) developed MDD: 25 (9.7%) patients in the placebo without therapy, 26 (10.2%) in the placebo with therapy, 32 (12.5%) in the supplement without therapy, and 22 (8.6%) in the supplement with therapy group. None of the treatment strategies affected MDD onset. The odds ratio (OR) for supplements was 1.06 (95% CI, 0.87-1.29); for therapy, 0.93 (95% CI, 0.76-1.13); and for their combination, 0.93 (95% CI, 0.76-1.14; P for interaction, .48). One person in the supplementation with therapy group, died. Twenty-four patients in each of the placebo groups and 24 patients in the supplementation with therapy group were hospitalized, and 26 patients in the supplementation-only group were hospitalized. CONCLUSIONS AND RELEVANCE: Among overweight or obese adults with subsyndromal depressive symptoms, multinutrient supplementation compared with placebo and food-related behavioral activation therapy compared with no therapy did not reduce episodes of major depressive disorder during 1 year. These findings do not support the use of these interventions for prevention of major depressive disorder. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02529423.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Bot M, Brouwer IA, Roca M, et al. Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial. JAMA. 2019. PMID: 30835307. doi:10.1001/jama.2019.0556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。